Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxford University and GE Healthcare in cancer collaboration
The two-year collaboration is the first ever to focus on developing a comprehensive disease management program which will focus on improved staging of the disease using both imaging
The two-year collaboration is the first ever to focus on developing a comprehensive disease management program which will focus on improved staging of the disease using both imaging
The partnership includes various agreements with regard to commercialization of Vitro’s stem cell lines for use in R&D and cross licenses to fertility drug technology and products owned
Under the terms of the agreement, Genaissance will apply its HAP Technology with the goal of identifying the genetic markers. Genaissance and Otsuka will be co-owners of the
The goal of the study is to determine the safety and efficacy of the treatment. Efficacy will be measured by standardized tests for Parkinson’s patients, as well as
The trial has been designed to evaluate the efficacy of Modrenal in patients who have failed prior endocrine therapy with the new generation aromatase inhibitors. The study will
PNH is characterized by the onset of severe anemia, chronic fatigue and intermittent episodes of dark colored urine. Estimates suggest that 2,000 – 10,000 people in the US,
Defibrotide will be tested in combination with Melphalan, Prednisone, and Thalidomide (MPT) at approximately 10 cancer centers in Italy. The study is designed to assess the safety and
The past few decades have seen emerging infectious diseases arrive with greater frequency and with more virulence, with the Asia Pacific region becoming an epicenter for a number
Tarceva, co-developed by Roche, OSI Pharmaceuticals and Genentech, is an oral tablet indicated for daily administration, and is approved in the US, Canada, and Switzerland. It is the
At the end of February this year the companies voluntarily suspended Tysabri from the US market and all ongoing clinical trials based on reports of progressive multifocal leukoencephalopathy